Most importantly, the one large study of leptin therapy for human obesity, conducted by Amgen, failed to achieve its therapeutic endpoint for efficacy in an unselected population with obesity (59). The gene discussed is LEP; the disease is obesity due to melanocortin 4 receptor deficiency.